Pharmaceutical product patents are in direct competition with the once-thriving, generic drug industry. Iain Gillespie, of the University of Leicester explains how the EU halted the success of generic drugs, and how the Canadian approach differs.

Leading thinkers from around the globe look at how societal conditions foster successful innovations
The opinions expressed in this article/multimedia are those of the author(s) and do not necessarily reflect the views of CIGI or its Board of Directors.